Sunder Biomedical Tech. Co., Ltd. Statistics
Sunder Biomedical Tech. Co., Ltd. (4115) Stock Statistics & Valuation Metrics
Total Valuation
Sunder Biomedical Tech. Co., Ltd. has a market cap or net worth of TWD 418.20M. The enterprise value is ―.
- Market Cap
- TWD 418.20M
- Enterprise Value
- ―
Share Statistics
Sunder Biomedical Tech. Co., Ltd. has 60,000,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 60,000,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Sunder Biomedical Tech. Co., Ltd.’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -1.00%.
- Return on Equity (ROE)
- -0.02
- Return on Assets (ROA)
- -0.01
- Return on Invested Capital (ROIC)
- -1.00%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 2.18M
- Profits Per Employee
- -46.99K
- Employee Count
- 346
- Asset Turnover
- 0.59
- Inventory Turnover
- 5.47
Valuation Ratios
The current PE Ratio of Sunder Biomedical Tech. Co., Ltd. is 71.41. Sunder Biomedical Tech. Co., Ltd.’s PEG ratio is -25.85.
- PE Ratio
- 71.41
- PS Ratio
- 0.57
- PB Ratio
- 0.54
- Price to FCF
- -8.99
- Price to Operating Cash Flow
- 7.00
- PEG Ratio
- -25.85
Income Statement
In the last 12 months, Sunder Biomedical Tech. Co., Ltd. had revenue of 753.45M and earned -16.26M in profits. Earnings per share was -0.27.
- Revenue
- 753.45M
- Gross Profit
- 102.48M
- Operating Income
- -18.33M
- Pretax Income
- -25.74M
- Net Income
- -16.26M
- EBITDA
- 68.43M
- Earnings Per Share (EPS)
- -0.27
Cash Flow
In the last 12 months, operating cash flow was 59.51M and capital expenditures -106.06M, giving a free cash flow of -46.54M billion.
- Operating Cash Flow
- 59.51M
- Free Cash Flow
- -46.54M
- Free Cash Flow per Share
- -0.78
Dividends & Yields
Sunder Biomedical Tech. Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.13%
- Earnings Yield
- 1.39%
Stock Price Statistics
- Beta
- 0.37
- 52-Week Price Change
- -16.02%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 42.50
- Average Volume (3m)
- 46.20K
Financial Position
Sunder Biomedical Tech. Co., Ltd. as a current ratio of 1.32, with Debt / Equity ratio of 51.28%
- Current Ratio
- 1.32
- Quick Ratio
- 1.00
- Debt to Market Cap
- 0.76
- Net Debt to EBITDA
- 4.23
- Interest Coverage Ratio
- -1.94
Taxes
In the past 12 months, Sunder Biomedical Tech. Co., Ltd. has paid -9.48M in taxes.
- Income Tax
- -9.48M
- Effective Tax Rate
- 0.37
Enterprise Valuation
Sunder Biomedical Tech. Co., Ltd. EV to EBITDA ratio is 7.47, with an EV/FCF ratio of -15.16.
- EV to Sales
- 0.96
- EV to EBITDA
- 7.47
- EV to Free Cash Flow
- -15.16
- EV to Operating Cash Flow
- 11.86
Balance Sheet
Sunder Biomedical Tech. Co., Ltd. has TWD 113.89M in cash and marketable securities with TWD 401.42M in debt, giving a net cash position of -TWD 287.53M billion.
- Cash & Marketable Securities
- TWD 113.89M
- Total Debt
- TWD 401.42M
- Net Cash
- -TWD 287.53M
- Net Cash Per Share
- -TWD 4.79
- Tangible Book Value Per Share
- TWD 12.88
Margins
Gross margin is 16.63%, with operating margin of 0.53%, and net profit margin of 0.78%.
- Gross Margin
- 16.63%
- Operating Margin
- 0.53%
- Pretax Margin
- 0.30%
- Net Profit Margin
- 0.78%
- EBITDA Margin
- 12.81%
- EBIT Margin
- 0.53%
Analyst Forecast
The average price target for Sunder Biomedical Tech. Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -2.88%
- EPS Growth Forecast
- ―
